Business Wire

KAL Releases a Full Acquiring Host System for Banks

19.9.2023 19:02:00 EEST | Business Wire | Press release

Share

The latest version of KTH (Kalignite Terminal Host), from world-leading ATM software company KAL, provides banks with a highly scalable solution for processing transactions.

As part of the Kalignite software suite, KTH is best known as a host terminal handler that drives ATMs, kiosks and POS devices. It is also a robust and future-ready alternative to conventional host systems, suitable for networks of all sizes and complexities.

With the key release of version 3, KTH has evolved into a fully integrated acquiring host. As the demand for resilient and innovative banking grows, today’s financial institutions can now leverage KAL’s solution to deliver a whole ‘host’ of additional capabilities - including end-to-end transaction processing, card scheme gateway support and advanced security. At a business level, KTH delivers cost reductions along with a superior transaction set. It also increases banks’ abilities to differentiate in the market and enhance the customer experience.

Highly scalable host software that’s built to last and designed to evolve

KTH runs in a low-cost hardware environment on virtual servers in the cloud or OnPrem – helping banks reduce total cost of ownership. It is tightly integrated with KAL’s K3A application and KTC management system. The user-friendly KTH Design Studio is included as standard and is similar to K3A’s development environment. Banks already using K3A have the added benefit of being able to apply their existing skills to KTH and tightly integrate the ATM with the host.

Consistent with its original release, the new version of KTH comes with pre-built components, configurable core code and virtualization support that accelerates software development timelines. It is engineered for versatility – making it quicker and easier for banks to support new ATM transaction types when needed.

In the words of KAL CEO Aravinda Korala:

“As banks grow more reliant on ATMs to deliver services, there is a greater demand for streamlined software development and support for new transaction types. KTH thrives in this context as a fully integrated acquiring host. It has a superior transaction set and an architecture that is engineered to scale as needed. As an alternative to conventional host systems, the KTH of today is more competitive than ever before – unlocking mission-critical support and new possibilities for bank delivery channels.”

About KAL

KAL ATM Software (est. 1989) is a world-leading ATM software company and the preferred supplier for global megabanks. The company specializes in software solutions for ATM networks of all sizes and complexities – allowing banks to gain control, reduce costs, increase functionality, and improve competitiveness.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Marylin Bell, Head of Marketing, KAL ATM Software
Email: Marylin.Bell@kal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea

Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release

Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55

Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release

As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The

SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release

The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye